SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmace…

According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at ...

Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition

Astria Therapeutics, Inc. acquired by BioCryst for $13 per share, with the deal set to finalize in 1Q26. Click here to read ...

SciSparc Ltd: SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage ...

According to the agreement, SciSparc's pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWI ...

The Boyar Value Group's Q3 2025 Letter

Boyar Value Group reviews 3Q’s record rally, AI-driven gains, and credit risks. See why selectivity and discipline matter ...